Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Reckitt Benckiser Group PLC American Depository Shares (ADSs) between January 13, 2021, and July 28, 2024, alleging that the company misled investors regarding the safety of its Enfamil baby formula [1][2]. Allegations - The lawsuit claims that Reckitt failed to inform investors and consumers about the increased risk of necrotizing enterocolitis (NEC) in preterm infants consuming its cow's milk-based formula, Enfamil, and the potential negative impact on sales and legal exposure [2]. - A jury in Illinois awarded $60 million in a case against Mead Johnson, finding negligence in failing to warn about the risks associated with cow's milk-based formula, which led to a significant drop in Reckitt's ADS price [3]. - Following a similar case in Missouri, where Abbott Laboratories was found liable for NEC-related damages, Reckitt's ADS price also experienced a notable decline [4]. Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file a motion by August 4, 2025, but participation is not required to be eligible for recovery [5].
RBGLY Investor Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against Reckitt Benckiser Group PLC